Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children

Competing Interest Statement

The authors R.P.G, Y.R.D, C.R.I, L.C.H. M.P.B, D.V.M, N.P.P, C.V.S, A.P.D, E.G.O, Y.C.E, J.C.F.P, M.S.M, M.D.E, J.M.E.P, Y.I.H, M.E.T.R declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors B.P.M, M.R.G, B.S.R, L.M.R.N, R.P.N, R.G.M, T.H.G, T.F.B, I.C.Q, S.F.C, Y.C.R, D.S.M, Y.G.V, Y.V.B, D.G.R, V.V.B work at Finlay Vaccine Institute or the Centre of Molecular Immunology, institutions that develop and manufacture the vaccine candidates but they have not received an honorarium for this paper. B.S.R., S.F.C., Y.C.R, L.R.N., D.S.M., Y.V.B., D.G.R. and V.V.B., have filed patent applications related to the vaccine SOBERANA 02. D.D and A.B work at Pasteur Institute of Iran and are co-developer of the vaccines

Clinical Trial

RPCEC00000374

Clinical Protocols

https://rpcec.sld.cu/ensayos/RPCEC00000374-Sp

Funding Statement

This work was supported by the Finlay Vaccine Institute, BioCubaFarma and the National Funds for Sciences and Technology from the Ministry of Science, Technology and Environment (FONCI-CITMA-Cuba, contract 2020-20).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was approved by the Ethical Committee at the Juan Manuel Marquez Pediatric Hospital and endorsed by the Cuban National Pediatric Group.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes